Candel Therapeutics Inc. (CADL) stock
Price, quality score, analyst targets, a 30-day Kronos AI forecast and a Shariah screen for Candel Therapeutics Inc., updated every trading day.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Price
$8.67
+5.09% today
Market cap
$631M
Overall quality
40/100
Kronos AI 30-day
+18.0%
8 of 8 simulated paths end higher
Candel Therapeutics Inc. (CADL) is a Health Care company in Biotechnology: Biological Products (No Diagnostic Substances), worth $631M. It trades at $8.67, up 5.09% today. Its overall quality score is 40 out of 100, ranked against the whole US market. 6 analysts' average target of $21.50 implies +148.0% from today's price. Kronos AI's 30-day forecast is +18.0% (8 of 8 simulated paths end higher).
Open the full interactive analysis →Charts, technical signals, DCF fair value and ownership
Analyst price targets
| Average target | $21.50 |
| Low – high | $16.00 – $25.00 |
| Analysts | 6 |
| Upside to average | +148.0% |
Kronos AI 30-day forecast
| Expected close | $9.73 (+18.0%) |
| Likely range | +12.9% … +22.5% |
| As of | 2026-10-27 |
8 of 8 simulated paths end higher.
Quality scores
| Profitability | 38 |
| Solvency | 48 |
| Growth | 33 |
| Overall | 40 |
| P/E | — |
Shariah screen
| Business activity | Passes |
| Debt and cash (AAOIFI 30%) | Not checked for this listing |
Automated screen of business activity and AAOIFI's 30% debt and cash limits. The 5% impermissible-income test is not applied. Check with a scholar before deciding.
Similar companies in Biotechnology: Biological Products (No Diagnostic Substances)
For information only, not investment advice. Prices updated: 2026-10-29.